|
|
News for:
|
|
For this drug, our server compiled this detailed Chemical Profile.
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
|
Click the Chemical Profile link above for detailed information.
Visit Betterchem's Drug Index for
- Exclusivity
Patents and market exclusivity
- Drug Information
Prescribing and other
information
- DMFs
Type 2 drug master files
- Databases
Free access to database search
- 21 CFR
FDA regulations for this drug
- Federal Register
FR search results for this drug
- Drug Recalls
For Rx's using this API
|
|
|
| |
FDA Approval Activities for this Drug
Zemplar (paricalcitol injection), Abbott NDA 20-819/S7, S11 2/24/03 3/10/03
Zemplar (paricalcitol injection), 5 mcg/mL Abbott NDA 20-819/S-003 2/2/00 2/4/00 2/4/00
Zemplar Indicated: For the prevention and treatment of secondary
hyperparathyroidism associated with chronic renal failure.
Zemplar (paricalcitol) Injection Abbott NDA 20-819 Zemplar (paricalcitol) Injection, Abbott Laboratories | Zemplar (paricalcitol) Capsules, Abbott Laboratories, Approval | Zemplar (paricalcitol) Injection, Abbott Labs, Labeling Revision
Visit Betterchem's Drug Index for FDA's latest approval information.
|
|